teva pharmaceutical ind ltd
Transactions by TEVA PHARMACEUTICAL IND LTD (TEVA) in the last 6 months
Teva Pharmaceutical Industries Limited (NYSE:TEVA) entered into a definitive agreement to acquire Auspex Pharmaceuticals, Inc. (NasdaqGM:ASPX) for $3.2 billion in cash on March 29, 2015. Under the terms of the deal Teva will commence a tender offer for all of the outstanding shares of Auspex at $101.00 per share in cash. The transaction is expected to be funded with cash on hand by Teva. Following the successful completion of the tender offer, Teva will acquire all remaining ...
CMEA Ventures VII, L.P.
Deerfield Capital, L.P.
Deerfield Management Company, L.P.
Deerfield Private Design Fund II, L.P.
Deerfield Private Design International II, Ltd.
Deerfield Special Situations Fund, LP
Deerfield Special Situations International Master Fund, L.P.
Foresite Capital Management, L.L.C.
Oxford Finance LLC
Panorama Capital I, L.P.
Thomas, McNerney & Partners
Thomas, McNerney & Partners II, L.P.
G & W Laboratories, Inc. signed an agreement to acquire Sellersville, Pennsylvania facility from Teva Pharmaceutical Industries Limited (NYSE:TEVA) on March 2, 2015. The transaction includes the grant to G & W of exclusive rights to sell up to two additional Teva products in the U.S. under G & W's label, which Teva will continue to manufacture at its Zagreb, Croatia facility. G & W Laboratories will offer employment to all the employees located in acquire Sellersville. ...
8800 Doral LLC acquired 78,130-square-foot building on 11.9 acres of land from Teva Pharmaceutical Industries Limited (NYSE:TEVA) for $26 million on January 14, 2015.
Soros Fund Management LLC sold a certain unknown stake in Teva Pharmaceutical Industries Limited (NYSE:TEVA) on November 16, 2014.
|No competitor information is available for TEVA.|
|View Industry Companies|
|Price/Cash Flow||--||Not Meaningful|